Argenx’s Vyvgart shows durability in myositis and Sjögren’s

Argenx's Vyvgart first gained approval by the FDA for generalised myasthenia gravis (gMG) in 2021. Vyvgart first gained approval by the FDA for generalised myasthenia gravis (gMG) in 2021. argenx is already running Phase III trials of Vyvgart in both myositis and Sjögren’s. Credit: Sheldon Cooper/SOPA Images/LightRocket via Getty Images Argenx’s Vyvgart (efgartigimod alfa-fcab) shows lengthy benefit for myositis and Sjögren’s disease, setting up its anticipated Phase III readouts. The data presented at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, taking place in London from 3 to 6 June, has shown durability up to a year in…

Source: Clinical Trials Arena